Effects of Erbie San on Walker-256 liver cancer and adjustment to unbalance of VEGF/endostatin in rats.
- Author:
Shumei WANG
1
;
Xiaoyu XU
;
Wenliang ZHANG
;
Ao LI
;
Wei DONG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Carcinoma 256, Walker; blood; pathology; Drugs, Chinese Herbal; pharmacology; Endostatins; blood; Gene Expression Regulation, Neoplastic; drug effects; Liver Neoplasms; blood; pathology; Male; Neovascularization, Pathologic; blood; pathology; Rats; Rats, Wistar; Tumor Burden; drug effects; Vascular Endothelial Growth Factor A; blood
- From: China Journal of Chinese Materia Medica 2009;34(1):89-91
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the anticancer effects of Erbie San on the rats bearing Walker-256 liver cancer and the potential mechanism of its angiogenesis effects.
METHODWistar rats bearing Walker-256 liver cancer were used in this study. The experimental groups were treated with Erbie San 1.25, 2.5, 5 g x kg(-1) x d(-1), and 5-Fluorouracil injection 75 mg x kg(-1), respectively. The tumor's weight, the expression of VEGF, Endostatin and the ratio of VEGF/endostatin in serum of each groups were observed.
RESULTCompared to the model group, Erbie San 2.5, 5 g x kg(-1) x d (-1) and 5-Fluorouracil injection groups can reduce the tumor's weight significantly (P<0.05 or P<0.01). The expression of VEGF was reduced, while endostatin was increased, and the ratio of VEGF/endostatin was reduced (P<0.05 or P<0.01).
CONCLUSIONErbie San can effectively inhibit the growth of Walker-256 liver cancer of rats and can inhibit the expression of VEGF but increase the expression of endostatin, which suggest that Erbie San has the inhibition of angiogenesis which is responsible for its anticancer effects.
